Adalvo are pleased to announce the successful DCP submission for Afatinib 20, 30, 40, 50mg film-coated tablets.
Based on the reference brand, GIOTRIF, Afatinib is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC).
The brand sold approximately $305 Million globally in 2022, according to IQVIA.
The successful development of this product further highlights Adalvo's ability to offer difficult-to-make, high-value products to their partners.
As a company committed to their oncology portfolio, Adalvo offers an array of dossiers and aims to assist their partners in overcoming any challenges that may arise. Our oncology dossiers are, but not limited to:
Partner up now!
At Adalvo, there are no half measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Reach out to your preferred Business Partner below to access Adalvo's Oncology dossiers.
arni.baldursson@adalvo.com - Head of Global BD&L
camila.reinoso@adalvo.com - LATAM (exc. Brazil)
marta.puig@adalvo.com - South Europe
ajish.rajan@adalvo.com – Central & Eastern Europe, Russia & CIS#
bruno.alves@adalvo.com - Brazil
jose.rendueles@adalvo.com- North Europe, APAC, MENA & Israel
marc.nolasco@adalvo.com - Central and Western Europe
paulo.rodriguez@adalvo.com – Europe
supreet.sharma@adalvo.com – UK/Ireland, North America & South Africa
Click on your preferred Business Partner and get in touch today!